Inactive Instrument

News BioLineRX Ltd. TEL AVIV STOCK EXCHANGE

Equities

IL0011015182

Summary

Unlock all the news: Be the first to know and act before the market!

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapy Applications in Sickle Cell Disease	May. 31	AQ
BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	May. 30	CI
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	May. 29	AQ
Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024	May. 28
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	May. 28	PU
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 28	CI
BioLineRx Ltd. announced that it has received $26 million in funding from Kreos Capital Management (UK) Limited	May. 27	CI
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	May. 24	CI
BioLineRx to Report First Quarter 2024 Results on May 28, 2024	May. 22	PR
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	May. 20	AQ
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	May. 06	PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	Apr. 17	PU
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	Apr. 17	CI
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	Apr. 10	PR
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	Apr. 10	CI
BioLineRx Announces $6 Million Registered Direct Offering	Apr. 02	AQ
BioLineRx Shares Fall After $6 Million Registered Direct Offering	Apr. 01	MT
BioLineRx : Form 20-F/A (Amendment No. 1	Mar. 28	PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	Mar. 27	AQ
BioLineRx : Annual Report on Form 20-F FOR 2023	Mar. 26	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioLineRX Ltd. TEL AVIV STOCK EXCHANGE

Equities

IL0011015182

Summary

Filters